Cargando…
Risk of cancer in patients with fecal incontinence
BACKGROUND: Fecal incontinence may be an early symptom of cancer, but its association with cancer remains unclear. We examined the risk of selected cancers, including colorectal cancer, other gastrointestinal cancers, hormone‐related cancers, and lymphoma, in patients with fecal incontinence. METHOD...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797632/ https://www.ncbi.nlm.nih.gov/pubmed/31468727 http://dx.doi.org/10.1002/cam4.2509 |
_version_ | 1783459872307675136 |
---|---|
author | Adelborg, Kasper Veres, Katalin Sundbøll, Jens Gregersen, Hans Sørensen, Henrik Toft |
author_facet | Adelborg, Kasper Veres, Katalin Sundbøll, Jens Gregersen, Hans Sørensen, Henrik Toft |
author_sort | Adelborg, Kasper |
collection | PubMed |
description | BACKGROUND: Fecal incontinence may be an early symptom of cancer, but its association with cancer remains unclear. We examined the risk of selected cancers, including colorectal cancer, other gastrointestinal cancers, hormone‐related cancers, and lymphoma, in patients with fecal incontinence. METHODS: Using Danish population‐based registries, all patients with hospital‐based diagnoses of fecal incontinence during 1995‐2013 were identified. We calculated cumulative incidences of cancers. As a measure of relative risks, we computed standardized incidence ratios (SIRs), that is, the observed number of cancers relative to the expected number based on national incidence rates by sex, age, and calendar year. RESULTS: Among 16 556 patients with fecal incontinence, the cumulative incidence of colorectal cancers, other gastrointestinal cancers, hormone‐related cancers, and lymphoma each was less than 0.4% after 1 year. It increased to under 3% after 10 years. The SIR for any cancer during 19 years of follow‐up was 1.12 [95% confidence interval (CI), 1.06‐1.19]. The SIRs during the first year were 2.31 (95% CI, 1.65‐3.13) for colorectal cancer, 1.56 (95% CI, 0.89‐2.54) for other gastrointestinal cancers, 1.00 (95% CI, 0.72‐1.35) for hormone‐related cancers, and 2.02 (95% CI, 1.01‐3.61) for lymphoma. Beyond 1 year, the SIR reached unity for other gastrointestinal cancers, hormone‐related cancers, and lymphoma, while a reduced risk was observed for colorectal cancer (SIR = 0.77, 95% CI, 0.59‐0.98). CONCLUSIONS: Fecal incontinence was a marker of cancer, especially gastrointestinal cancers and lymphoma within 1 year, which presumably is driven partly by reverse causation. However, the absolute risks were low. Heightened diagnostic efforts may explain in part the increased short‐term risk of colorectal cancers. |
format | Online Article Text |
id | pubmed-6797632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67976322019-10-21 Risk of cancer in patients with fecal incontinence Adelborg, Kasper Veres, Katalin Sundbøll, Jens Gregersen, Hans Sørensen, Henrik Toft Cancer Med Cancer Prevention BACKGROUND: Fecal incontinence may be an early symptom of cancer, but its association with cancer remains unclear. We examined the risk of selected cancers, including colorectal cancer, other gastrointestinal cancers, hormone‐related cancers, and lymphoma, in patients with fecal incontinence. METHODS: Using Danish population‐based registries, all patients with hospital‐based diagnoses of fecal incontinence during 1995‐2013 were identified. We calculated cumulative incidences of cancers. As a measure of relative risks, we computed standardized incidence ratios (SIRs), that is, the observed number of cancers relative to the expected number based on national incidence rates by sex, age, and calendar year. RESULTS: Among 16 556 patients with fecal incontinence, the cumulative incidence of colorectal cancers, other gastrointestinal cancers, hormone‐related cancers, and lymphoma each was less than 0.4% after 1 year. It increased to under 3% after 10 years. The SIR for any cancer during 19 years of follow‐up was 1.12 [95% confidence interval (CI), 1.06‐1.19]. The SIRs during the first year were 2.31 (95% CI, 1.65‐3.13) for colorectal cancer, 1.56 (95% CI, 0.89‐2.54) for other gastrointestinal cancers, 1.00 (95% CI, 0.72‐1.35) for hormone‐related cancers, and 2.02 (95% CI, 1.01‐3.61) for lymphoma. Beyond 1 year, the SIR reached unity for other gastrointestinal cancers, hormone‐related cancers, and lymphoma, while a reduced risk was observed for colorectal cancer (SIR = 0.77, 95% CI, 0.59‐0.98). CONCLUSIONS: Fecal incontinence was a marker of cancer, especially gastrointestinal cancers and lymphoma within 1 year, which presumably is driven partly by reverse causation. However, the absolute risks were low. Heightened diagnostic efforts may explain in part the increased short‐term risk of colorectal cancers. John Wiley and Sons Inc. 2019-08-29 /pmc/articles/PMC6797632/ /pubmed/31468727 http://dx.doi.org/10.1002/cam4.2509 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Prevention Adelborg, Kasper Veres, Katalin Sundbøll, Jens Gregersen, Hans Sørensen, Henrik Toft Risk of cancer in patients with fecal incontinence |
title | Risk of cancer in patients with fecal incontinence |
title_full | Risk of cancer in patients with fecal incontinence |
title_fullStr | Risk of cancer in patients with fecal incontinence |
title_full_unstemmed | Risk of cancer in patients with fecal incontinence |
title_short | Risk of cancer in patients with fecal incontinence |
title_sort | risk of cancer in patients with fecal incontinence |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797632/ https://www.ncbi.nlm.nih.gov/pubmed/31468727 http://dx.doi.org/10.1002/cam4.2509 |
work_keys_str_mv | AT adelborgkasper riskofcancerinpatientswithfecalincontinence AT vereskatalin riskofcancerinpatientswithfecalincontinence AT sundbølljens riskofcancerinpatientswithfecalincontinence AT gregersenhans riskofcancerinpatientswithfecalincontinence AT sørensenhenriktoft riskofcancerinpatientswithfecalincontinence |